Last reviewed · How we verify

Injection, botulinum toxin + corticoid

Assistance Publique - Hôpitaux de Paris · Phase 3 active Small molecule

Botulinum toxin blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions, while the corticoid provides anti-inflammatory effects.

Botulinum toxin blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions, while the corticoid provides anti-inflammatory effects. Used for Spasticity or muscle hyperactivity disorders (investigational combination), Chronic pain conditions with muscular component (investigational).

At a glance

Generic nameInjection, botulinum toxin + corticoid
SponsorAssistance Publique - Hôpitaux de Paris
Drug classNeurotoxin + corticosteroid combination
TargetAcetylcholine release machinery (SNARE complex); glucocorticoid receptor
ModalitySmall molecule
Therapeutic areaNeurology / Dermatology / Pain Management
PhasePhase 3

Mechanism of action

Botulinum toxin irreversibly inhibits acetylcholine release by cleaving SNARE proteins, causing temporary muscle paralysis. The co-formulated corticoid reduces local inflammation and may enhance therapeutic efficacy or reduce immune responses to the toxin. This combination targets both neuromuscular and inflammatory pathways in the injection site.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: